Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.61 |
| ▸ | MAPT | P10636 | 7/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.61 |
| ▸ | USP2 | O75604 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19319416 | 0.82 | MAPT (0.54) | MAPTLMNATSHRRAB9APOLB | |
| SCHEMBL24771112 | 0.82 | ALDH1A1 (0.51) | SMN1; SMN2MAPTLMNAALDH1A1KDM4E | |
| SCHEMBL19351559 | 0.81 | MAPT (0.44) | SMN1; SMN2MAPTLMNAALDH1A1KDM4E | |
| SCHEMBL19351552 | 0.81 | MAPT (0.44) | SMN1; SMN2MAPTLMNAALDH1A1KDM4E | |
| SCHEMBL19319359 | 0.81 | MAPT (0.44) | SMN1; SMN2MAPTLMNAALDH1A1KDM4E | |
| SCHEMBL19319382 | 0.80 | MAPT (0.58) | SMN1; SMN2MAPTLMNAALDH1A1USP2 | |
| SCHEMBL19319202 | 0.79 | MAPT (0.52) | SMN1; SMN2MAPTLMNAALDH1A1HTT | |
| SCHEMBL19319233 | 0.79 | MAPT (0.52) | SMN1; SMN2MAPTLMNAALDH1A1HTT | |
| SCHEMBL19319187 | 0.79 | MAPT (0.52) | SMN1; SMN2MAPTLMNAALDH1A1HTT | |
| SCHEMBL19319235 | 0.79 | MAPT (0.52) | SMN1; SMN2MAPTLMNAALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426245-B1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20210230176-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2021-07-29 | — | — | US | disclosed |
| US-10934306-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200199143-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2020-06-25 | — | — | US | disclosed |
| US-20190084994-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARM INC (US) | 2019-03-21 | — | — | US | disclosed |
| US-10179792-B2 | Hepatitis B antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2019-01-15 | — | — | US | disclosed |
| WO-2017155844-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-20170253609-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | disclosed |
| US-20170253609-A1 | HEPATITIS B ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10179792-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | SMN1; SMN2 4765/4885MAPT 4660/4885LMNA 453/4885 |
| US-20190084994-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | SMN1; SMN2 4765/4885MAPT 4660/4885LMNA 453/4885 |
| US-20210230176-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | SMN1; SMN2 4765/4885MAPT 4660/4885LMNA 453/4885 |
| US-20200199143-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | SMN1; SMN2 4765/4885MAPT 4660/4885LMNA 453/4885 |
| US-10934306-B2 | Hepatitis B antiviral agents | HAVCR2, PYGL, SLC10A1 | SMN1; SMN2 4765/4885MAPT 4660/4885LMNA 453/4885 |
| US-20170253609-A1 | HEPATITIS B ANTIVIRAL AGENTS | HAVCR2, PYGL, SLC10A1 | SMN1; SMN2 4765/4885MAPT 4660/4885LMNA 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.